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WE have examined the effects of intravenous infusion of
recombinant human tumour necrosis factor (rh-TNF) on
serum activity of phospholipase A (PLAe) in patients with
malignancies. Nine patients received a 24 h continuous
intravenous infusion ranging from 1.0 x 10SU/m to
3.0 10 U/me; 14 patients received a 5 day continuous
intravenous infusion ranging from 0.5 x 10 U/me/day to
3.0 10 U/me/day. Twenty one of 23 patients responded
with marked increases in serum PLA activity that were
detectable 3 h after the beginning of the rh-TNF infusion
and reached maximum levels at 18 h with a mean increase
of 16.2-fold. In patients receiving a 5 day rh-TNF infusion,
the highest levels ofPLA were observed after the first day
of infusion. Serum PLA activity declined continuously to
2.9-fold above baseline at the end of the infusion. A
significant correlation was noted between the dose of
infused rh-TNF and the maximum increase in PLAz
activity. To our knowledge, this is the first time that an
association between intravenous TNF administration and
induction of circulating PLAz in man has been established.
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Introduction
Phospholipase A2 is a lipolytic enzyme that
hydrolyses membrane associated phospholipids of
mammalian cells and initiates the arachidonic acid
cascade. Several of its end product eicosanoids
have well known proinflammatory activity.
2 Recent
studies have demonstrated that phospholipase a2
(PLA2) is secreted extracellularly in inflammatory
sites including synovial fluids in inflammatory
arthritides, peritoneal fluid in peritonitis,
4 and sere
in septic shock. 5’6 PLA2 injected into skin, joints
or paws of experimental animals elicits a time and
dose-dependent inflammatory reaction. We have
previously shown that intravenous injection of
endotoxin in experimental animals or human
volunteers,
1 was associated with a marked increase
in circulating PLA2 activity. Furthermore, in-
travenous infusion of PLA2 reproduces many
features of endotoxaemia.
Bacterial and toxic insults lead to the rapid
synthesis and release of cytokines including IL-1
and TNF.1>4 We recently demonstrated that these
two cytokines markedly enhance the synthesis and
extracellular release of PLA2 from cultured
mammalian cells.
5 Infusion of TNF in man elicits
clinical and haemodynamic manifestations similar to
those caused by endotoxin.1<7 Since infusion of
PLA2 leads to similar manifestations, it was of
significant interest to determine whether re-
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combinant human TNF (rh-TNF), given intraven-
ously, would be followed by intravascular secretion
of PLA2 in vivo. The finding that TNF infusions,
without prestimulation with endotoxin, cause
increase in circulating PLA2 would reinforce the
link between proximal cytokine response and PLA2
activity, and may provide insights into the
mechanisms of the proinflammatory activity of
TNF. Such findings may also indicate that TNF has
an impact on activation of the PLAe-initiated
arachidonic acid cascade. The present study
demonstrates that intravenous administration of
TNF in humans leads to a rapid and marked
increase in circulating PEA2 activity.
Materials and Methods
Patient selection and therapy: Twenty-three patients
with cancer (Tables 1 and 2) received intravenous
infusion of human recombinant tumour necrosis
factor (rh-TNF) (Asahi Chemical Industry Com-
pany of America, New York, NY). Nine patients
(group I) received a 24 h continuous intravenous
infusion,
1 and 14 patients (group II) received a 5
day continuous intravenous infusion.7 In the first
group the rh-TNF dose varied from 1.0
105 u/me/day to 3.0 x 105 u/me/day. In the second
group the daily dose ranged from 0.5 x 10 u/me/
day to 3.0 105 U/me/day. The first group also
Mediators of Inflammation Vol 1992 235W. Pruzanski et al
received etoposide (Bristol-Myers Oncology, Wall-
ingford, CT), 80 mg.m-2 by continuous in-
travenous infusion for 3 days, starting 24 h prior to
rh-TNF infusion. Both groups were pretreated with
indomethacin 50 mg on the evening before and
q.i.d, thereafter for 24 h. All patients were hospita-
lized and monitored as described.
6<8 Sodium
chloride (0.9%) was infused at 150 ml.h for 24 h
prior to rh-TNF infusion, rh-TNF was diluted in
the same buffer and infused at a constant rate
(150-300 ml/day). In all patients, previous chemo-
therapy and/or radiotherapy was discontinued at
least 3 weeks prior to rh-TNF infusion.
Drugformulation" The rh-TNF used for this study had
a specific activity of 2.3 x 106 U/mg protein. One
unit was defined as the amount required to lyse 50%
of L-M cells in a 48 h assay. The preparation of
TNF used in this study contained less than 100 pg
of endotoxin per mg protein, as tested by the
Limulus lysate assay.
Enzyme assay" Phospholipase A2 assay was performed
as described, using autoclaved Escherichia coli
K12C600 labelled with [14C]oleic acid as the
substrate.
19 Assays were performed in substrate
excess, using 2.8 x 108 E. coli per assay, corre-
sponding to 5.6 nmol of phospholipid with a
specific activity of 4120 cpm/nmol. In conditions
of substrate excess, the rate of substrate hydrolysis
was linear with reaction times up to 30 min, over a
five-fold range of enzyme concentration. One unit
of PLA2 activity is defined as the amount of enzyme
activity that hydrolyses 56 pmol of E. coli phospho-
lipid in 30 min. Activity of serum PLA2 after
rh-TNF infusion was tested at different pH and
calcium concentrations as described previously. 19’2
The effect of neutralizing polyclonal antibody
(NPA) against rh-PLA2 (lot 207, Biogen, Cam-
bridge, MA) on rh-TNF-induced endogenous PLA2
was tested by incubating NPA with PLA.-
containing sera for 60 min at room temperature, and
testing the mixture for residual PLA2 activity. The
direct effect of rh-TNF on PLA2 activity in vitro was
tested using E. coli phospholipid substrate, rh-TNF
in concentrations of up to 1000 U/ml were pre-
incubated with PLA2 for 30 min at room
temperature prior to addition of substrate.
The reference range for normal serum PLA2
(n 143) is 149 +__ 69 (SD) U/ml with a range of
40-365 U/ml. Serum samples from patients infused
with rh-TNF were coded and assayed for PLA2
activity without any knowledge regarding the
relationship of the sample to the time, dose or the
nature of infusion. The results were simultaneously
exchanged and analysed in two centres.
Statistical anasis: Statistical analysis was performed
by standard tests including correlation coefficient
and Student’s t-test.
Results
Group I consisted of three men and six women
ranging in age from 25 to 73 y (mean 52.2 y). The
primary tumours of these patients are summarized
in Table 1. Metastases, mainly to the liver and lung,
were present in all patients. One patient had a past
history of cancer of the breast, one had tuberous
sclerosis and one had mild, chronic pancreatitis.
None had fever or infection preceding the rh-TNF
infusion. White blood cell count varied from 5 to
11 x 1012/1 with a normal differential count. All
patients had normal creatinine.
Before rh-TNF infusion six of the nine patients
had normal serum PLA2. In three patients, two with
renal cell carcinoma and one with cancer of the
colon, baseline PLA2 was elevated ranging from
727 U/ml-
to 2297 U /ml Seven of nine patients
responded to rh-TNF infusion with marked
increases in PLA2 (Table 1). Increase in PLA2
activity was evident at 3 h after beginning the
rh-TNF administration, and lasted for the entire
period of infusion. Maximal PLA2 activity (16.2-
fold) was observed at 18 h of infusion (Figure 1).
Levels of PLA2 remained elevated (1510-
38274 U/ml) in all three patients in whom the
serum was tested 24h after terminating the
infusion.
In group II, there were seven men and seven
women ranging in age from 37 to 70y (mean
55.4 y). The diagnoses are summarized in Table 2.
Metastases were detected in twelve of 14 patients.
No past diseases known to influence PLA2 activity,
such as pancreatitis, rheumatoid arthritis, infection
or fever were documented. All patients had normal
renal function (creatinine < 1.2 mg/dl). Peri-
pheral blood leukocyte count ranged from 4 to
14 x 1012/1 with normal differential counts.
Ten of 14 patients had normal serum PLA2
activity prior to rh-TNF infusion (Table 2). In four
patients, initial serum PLA2 levels were elevated
ranging from 604U/ml to 6397U/ml. All 14
patients demonstrated an increase in PLA2 activity
after initiation of the rh-TNF infusion (Table 2).
The activity was highest after the first day of
infusion (13-fold) and it gradually declined to 2.9
times higher than baseline after 5 days of infusion,
and two times higher than baseline 24 h after
termination of rh-TNF infusion (Fig. 2).
In both groups, there was a significant
correlation between the daily dose of rh-TNF
infused and the maximum increase in PLA2 activity
(p < 0.05) (Fig. 3).
PLA2 in the sera of rh-TNF infused patients was
calcium dependent, with optimal activity at 5 mM
and was completely inactivated by 2 mM EDTA.
The pH optimum was 7.5. Polyclonal antibodies
against human group II PLA2 completely neu-
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Table 1. Clinical/laboratory profile of patients who received continuous 24 h intravenous
infusion of rh-TNF
PLA2 U/ml
Dose of PLA2 U/ml peak during
No. Age Sex Diagnosis* rh-TNF U/m
2 pre-TNF TNF infusion
53 F Renal cell x 105 193 16458
liver
2 62 F Renal cell x 105 2297 2735
liver, lung
3 57 F Hepatoma x 105 105 2935
lung
4 34 F Colon, lung 2 x 105 364 585
kidney
peritoneum
5 54 F Renal cell 2 x 105 2093 27022
lung
6 73 M Colon 2 x 105 82 2211
lung, liver
7 25 M Colon 2 x 105 727 3151
liver
8 49 F Lung 2 x 105 115 11079
contralateral
lung
9 63 M Renal cell 3 x 105 270 38274
lung, skeletal
Top line, primary cancer; below, site of metastatic involvement.
Table 2. Clinical/laboratory profile of patients who received 5 day continuous intravenous
infusion of rh-TNF
PLA2 U/ml
Dose of PLA2 U/ml peak during
No. Age Sex Diagnosis* rh-TNF U/m2/day pre-TNF TNF infusion
55 F Lung 0.5 x 105 263 2191
skeletal
2 55 M Carcinoid 0.5 x 105 167 485
liver
3 54 F Skeletal 0.5 x 105 158 8676
lung, brain
4 37 F Ovarian 1.0 x 105 106 2505
liver
5 49 F Breast 1.0 x 105 178 9801
liver
6 55 M Colon 1.0 x 105 6397 13045
liver
7 45 M Renal 2.0 x 105 601 35056
pancreas
8 48 M Colon 2.0 x 105 264 25861
9 58 F Colon, pleura 2.0 x 105 265 7496
liver
10 67 F Uveal 2.4 x 105 311 18038
melanoma
lung
11 70 M Colon 2.4 x 105 604 8950
12 68 M Lung 2.4 x 105 287 23163
13 56 F Colon 3.0 x 105 224 5596
mesenteric
14 58 M Renal 3.0 x 105 1984 8311
peritoneum
Top line, primary cancer; below, site of metastatic involvement.
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FIG. 1. Phospholipase A in patients who received 24 h continuous
intravenous infusion of rh-TNF. Vertical bars, mean -t- SEM.
tralized (93%) PLA2 activity in the sera of rh-TNF
infused patients, rh-TNF or etoposide had no
detectable effect on the activity of purified PLA2 in
vitro.
Discussion
Extracellular phospholipase a2 (PLA2) has recently
been identified in synovial fluids in inflammatory
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FIG. 2. Phospholipase A in patients who received 5 day continuous
intravenous infusion of rh-TNF. Vertical bars, mean ___
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FIG. 3. Correlation between the dose of infused human recombinant TNF
and increase of phospholipase A2. Horizontal bars, means.
arthritides.
3 Subsequently, very high serum activity
of PLA2 was found in systemic inflammatory
processes such as septic shock5’6 and adult
respiratory distress syndrome.
6 Purified PLA2
instilled into the lungs
21 or injected into joints,
skin
7 or paws of experimental animals causes
marked dose and time-dependent inflammatory
reactions that are abolished by inhibitors of this
enzyme. Taken together, these results suggest that
PLA2 plays an important role in local and systemic
inflammatory processes. 22’23
Marked increases in circulating PLA2 have been
observed in animals challenged with endotoxin. In
such animals, the rise in the serum PLA2 activity
correlates with the fall in the mean arterial blood
pressure. When the PLA2-enriched fraction of septic
shock serum is infused into healthy rabbits, it
reproduces the clinical and haemodynamic changes
induced by endotoxin. Pretreatment of the
PLAe-enriched fraction by the PLA2 inhibitor,
p-bromophenacyl bromide, inhibits PLA2 activity
and abrogates the hypotensive effect.
Very high circulating PLA2 activity has been
found in patients with gram-negative septic shock.
6
In both retrospective
6 and prospective
24 studies, the
activity of PLA2 correlates with the Haemodynamic
Instability Score (p < 0.001). The above studies
have shown that PLA2 fulfils several of Lefer’s
criteriaas for a mediator of circulatory shock: (1) a
marked increase in circulatory PLA2 in response to
bacteria or their toxins; (2) hypotension caused by
PLA2 in experimental animals; and (3) correlation
of endogenous PLA2 levels with the severity of
hypotension in both animals and man. Further-
more, an inhibitor of PLA2, p-bromophenacyl
bromide, ameliorates these effects of PLA2. Taken
together, these data suggest that PLA2 is one of the
mediators of septic shock manifestations.
Several studies have recently examined the
relationship between PLA2 and cytokines. TNF
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exerts its impact on the cells through its binding to
cell surface receptors.
26 The interaction of TNF
with the receptors is associated with GTP binding
and increase in GTPase activity.
27 Furthermore, the
association of TNF and PLA2 has been reported by
several groups.
28---33 TNF stimulates PLA2 activity
in HL-60
32 and Balb/c 3T3 cells
3 and, conversely,
PLA2 activity is required for the transcriptional
activation of TNF gene expression. 32’33 Moreover,
inhibitors of PLA2 have been found to interfere
with the cytotoxic and cytolytic activity ofTNF28’29
and to block TNF-induced increases in macro-
phage-specific colony stimulating factor (M-CSF)
transcripts.
31
In human volunteers challenged intravenously
with endotoxin, marked increases in circulating
PLA2 followed transient increases in TNF.
1 This
temporal relationship is of particular interest, since
it has been found that bacterial or toxin challenge
in animals or in man leads to a prompt release of
cytokines such as IL-1 and TNF. The ensuing
clinical and haemodynamic changes, which in the
past were assumed to be related to bacterial toxins,
have recently been linked to the effects of cytokines.
TNF is capable of eliciting most, if not all, effects
of endotoxin. 11’12 It was therefore concluded that
TNF is one of the endogenous mediators of
endotoxic shock. 11’13’14 Recent studies have also
suggested that several physiological and metabolic
changes that are associated with malignant
processes are in fact mediated through TNF.
18
Several clinical trials with intravenous admin-
istration of rh-TNF have been performed in cancer
patients. 16’17’34 The cascade of events following
TNF infusions has not been elucidated. Transient
increases in circulating IL-6 have been observed in
cancer patients infused with TNF. The highest level
of IL-6 was observed after 3-6 h of TNF infusion,
and correlated with TNF dose.
35 We hypothesized
that TNF infusion will also lead to increased PLA2
activity. This postulate was based on the
observations that endotoxin infusion leads to
increases in TNF followed by high circulating
PI,A21 and that TNF enhances PLA2 synthesis and
secretion in vitro.
15 Many of the effects of TNF
depend on the local and systemic activation of the
cyclooxygenase pathway.
13 Furthermore, prosta-
glandins appear to play a role in mediating the
effects of TNF.
14 Thus, if the activity of PLA2 is
modulated by TNF, the role of eicosanoids in
proximal cytokine mediated reactions would
become more apparent.
In the present study we have shown that in 21
of 23 patients infusions of rh-TNF were associated
with significant increases in the activity of
circulating PLA2. The earliest serum PLA2
increases occurred 3 h after beginning the rh-TNF
infusion and maximal levels were observed at
18-24 h. Of interest is the fact that in the patients
who received 5 day rh-TNF infusion, the level of
circulating PLA2 declined after the first 24 h. This
phenomenon may be related to the previously
described decline in TNF levels that occurs in
patients who received 24 h continuous infusions.
16
Neither the relationship between the saturation of
TNF receptors and its impact on PLA2 release, nor
the intra-vascular/extravascular distribution of
PLA2 or its metabolism are known. However, the
maximal increase in PLA2 activity correlated with
the daily dose of rh-TNF. Therefore a dose-related
link was established between TNF and PLA2
activation. Thus, PLA2 is activated by both
endotoxin5’1 and by proximal cytokines. Since
PLA2 is proinflammatory and vasoactive, some
manifestations previously attributed to endotoxin
and tumour necrosis factor should probably be
attributed to PLA2 as well.
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